• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Quintiles adds two Prime Sites in effort to expand its global alliance program to 20 sites by year-end

Quintiles adds two Prime Sites in effort to expand its global alliance program to 20 sites by year-end

May 9, 2011
CenterWatch Staff

CRO Quintiles will soon announce the addition of two new sites to its elite Prime Sites program. Both in the U.K., they are: University Hospitals Birmingham NHS Foundation Trust; and the Royal Devon and Exeter Foundation Trust, with its academic arm Peninsula College of Medicine and Dentistry and the Royal Cornwall Hospital.

The new additions are part of Quintiles’ effort to ramp up its eight-site program, which launched in 2007, to a 20-site program by the end of the year, said Lisa Becker, vice president and global head of integrated patient and site strategies. The goal, she added, is to recruit 1,000 patients through the Prime Sites this year.

The Prime Sites are essentially very large, high-performing, usually hospital-based sites with which Quintiles has worked for years and with whom it desires a closer, more alliance-like relationship. The designation means Quintiles will provide access to all of its larger studies before offering them to other, non-Prime sites.

Part of the arrangement, said Becker, is that each site agrees to dedicate employees to working closely with a Quintiles Prime Site manager. This keeps the relationship close and expectations properly aligned.

According to Becker, the Prime Sites—which last year had enrolled a total of 300 patients in nearly 50 studies worldwide—have study start-up times about 30% faster than non-partner sites. The key to the program’s success, she said, has been Quintiles’ ability to harmonize operational processes, drive efficiencies in start up and build better relationships with site staff.

With the Prime Sites Program, Quintiles is attempting to blanket the globe with huge, high-recruiting sites that can accommodate studies best conducted in an inpatient setting, and in the most pressing therapeutic areas, said Becker. Quintiles Prime Sites thus far (excluding the two newest sites), starting with the most recently added, include:

  • The University of Nebraska Medical Center (UNMC), as of January 2011.
  • The Seoul National University Hospital (SNUH), in October 2010.
  • The Arizona State University (ASU) Center for Healthcare Innovation & Clinical Trials, part of the College of Nursing & Health Innovation, also in October 2010.
  • The University Malaya Medical Centre (UMMC) in Kuala Lumpur, Malaysia, in July 2010, the first site in Asia.
  • Kaiser Permanente’s Southern California Permanente Medical Group (SCPMG), in May 2009, the second U.S. site.
  • The University of Pretoria in South Africa, its third Prime Site, in September 2009.
  • Washington Hospital Center in Washington, D.C., became its second site in 2008.
  • Queen Mary College (the medical school at the University of London) became the first Prime Site in 2007.

Quintiles won’t reveal its future additions. But others are willing to speculate. Michael Martorelli, director at investment banking firm Fairmount Partners, consultant to the CRO industry and a long-time watcher of the space, said that with four Prime Sites in the U.S., three in the U.K., two in Asia and one in Africa, Latin America and Eastern Europe would be logical locations in which to establish a presence if trying to be truly global.

Martorelli also put China and India on his list and said it wouldn’t surprise him if Quintiles also added one or two more U.S. sites. He cited Boston, Cleveland, Chicago and Texas as locations with large medical institutions that would make good partners.

--Suz Redfearn

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing